Referring Clinicians
Thank you for your interest to consider your patients for early phase clinical trial enrollment. Here at the Auckland Cancer Trials Centre, we welcome referrals from across the whole of New Zealand.
This page contains the following information:
- An updated list of trials currently enrolling at our unit.
- Links to patient information summaries and key inclusion/exclusion criteria for each individual trial (feature in development)
- Instructions on how to refer your patients
Trials Recruiting at ACTC
| Tumour Stream | Trial Name | Study Description | Key Investigational Agent | Key Inclusion Criteria | Recruitment Status |
|---|---|---|---|---|---|
| Multiple tumour stream | GILEAD (GS-US-494-5484) | A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors | GS-4224 (small molecule oral PDL1 Inhibitor) | Advanced Solid Organ Malignancy with no further treatment options. TPS/CPS >10% in participants of the Biopsy Substudy | Recruitment Open - Phase 1b Dose Escalation Cohort and Biopsy Substudy Expected to open in 2nd quarter 2020 -Phase 2 Basket Dose Expansion Cohort: CPI Naïve -Melanoma, Renal, Urothelial, Gastric/GOJ, HNSCC,MSI High Cancer, Merkel Cell Carcinoma |
| Head and Neck Squamous Cell Carcinoma | BP40234-FAP | Phase 2 study to evaluate the therapeutic activity of RO6874281 in combination with Atezolizumab in patients with advanced and/or metastatic solid tumors | Atezolizumab (Anti PDL1) + IL2variant | HNSCC -Checkpoint inhibitor exposed (≥ 2nd line) | Recruiting |
| Upper Gastrointestinal (Advance) , Colorectal (Advance) | CITRON | Reducing Oxaliplatin Neurotoxicity: A Phase IB Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose-Finding and Proof-of-Concept Trial of Cimetidine in Gastrointestinal Cancer Patients | mFOLFOX OR CAPOX +/- cimetidine | First 2 cycles mFOLFOX + cimetidine or placebo assessing for acute neuropathy. | Recruiting |
| Colorectal (Metastatic) | Medimmune | A phase 1/2 study of Durvalumab and Monalizumab in Adult Subjects with Select Advance Solid Tumours | Durvalumab (antiPDL1) [D] + Monalizumab (anti CD94/NKG2A) [M] + Cetuximab (EGFR inhibitor) [C] | Cohort C2 : RAS, BRAF wildtype, microsatelite stable, must have been exposed to 5FU/Oxali/Irinotecan/Bevacizumab in 1 or 2 lines of therapy. Randomised to either (D+M+C) or (M+C) | Recruiting |
| Merkel Cell | MK-3475-913 | A phase 1 open label, multi-arm , multicenter study of MK-1308 in combination with pembrolizumab for subjects with advanced solid organ tumours | Pembrolizumab(antiPD1) | • Unresectable Stage III and Stage IV Merkel Cell Carcinoma • 1st line | Recruiting |
| Prostate (mCRPC) | MK-3475-365 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365) | Pembrolizumab +Olaparib or Pembrolizumab +Abiraterone | Cohort A: (Pembro + Olaparib)- Must have received docetaxel +/- second chemo agent, up to 2 generation hormonal manipulations allowed (e.g. abiraterone, enzalutamide) Cohort D (Pembro + Abiraterone + Pred)- Chemo naïve for mCRPC (docetaxel allowed in mCNPC setting), no prior 2ng generation hormonal manipulation OR progressed on enzalutamide. | Recruiting |
| Melanoma (Fully resected stage III and IV) | CA2098FC | Phase 1, randomized, double-blinded study to compare the PK of Process D Nivolumab to Process C Nivolumab administered after complete resection of Stage IIIa/b/c/d or Stage IV Melanoma | Nivolumab (Process D) | Completely resected Stage III/ IV Melanoma Randomization within 12 weeks of definitive surgery. No adjuvant radiotherapy permitted | Recruitment open but all available slots have been allocated to already referred patients |
| Melanoma, NSCLC, SCLC | NP40435 | Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumours | PD1/TIM3 bi-specific antibody | -Melanoma: after PD1+/- CTLA4 inhibitor (includes uveal melanoma) -NSCLC: CPI experienced, post platinum, must have received at least 4 months of CPI, PDL1>1% -SCLC: CPI-naive | Recruitment to commence soon |
How to Refer
Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)
Email us for any other inquiries: infoACTC@adhb.govt.nz
Auckland Cancer Trials Centre
Auckland City Hospital,
2, Park Road, Grafton,
1023, Auckland, New Zealand
Patient Referrals
Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)